The Pharmacogenetic Impact on the Pharmacokinetics of ADHD Medications
Reference35 articles.
1. Volkow ND, Swanson JM (2013) Clinical practice: adult attention deficit-hyperactivity disorder. N Engl J Med 369:1935–1944
2. Posner J, Polanczyk GV, Sonuga-Barke E (2020) Attention-deficit hyperactivity disorder. Lancet Lond Engl 395:450–462
3. Stevens T, Sangkuhl K, Brown JT et al (2019) PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics 29:136–154
4. Elsayed NA, Yamamoto KM, Froehlich TE (2020) Genetic influence on efficacy of pharmacotherapy for pediatric attention-deficit/hyperactivity disorder: overview and current status of research. CNS Drugs 34:389–414
5. Brown JT, Bishop JR, Sangkuhl K et al (2019) Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. Clin Pharmacol Ther 106:94–102